Establishing the Pennsylvania Drug Shortage Reporting System; and imposing duties on the Department of Health.
Impact
The impact of HB 1249 on state laws revolves around enhancing communication between drug manufacturers and health authorities in Pennsylvania. By imposing notification requirements on manufacturers and wholesale distributors regarding drug shortages and production issues, the bill aims to minimize disruptions in the supply chain of essential medications. The legislation mandates the Department of Health to keep a comprehensive list of lifesaving drugs in shortage, thus enabling timely responses to threats against public health due to medication unavailability.
Summary
House Bill 1249 establishes the Pennsylvania Drug Shortage Reporting System to address the critical issue of lifesaving drug shortages within the state. This system is designed to improve the transparency and accessibility of information regarding the availability of lifesaving drugs in Pennsylvania. Manufacturers are required to notify the Department of Health of any discontinuance or interruption in the production of lifesaving drugs, as well as the reasons for such interruptions. This information will be accumulated in a centralized reporting system, accessible to healthcare professionals, patients, and individuals requiring lifesaving medications.
Sentiment
The sentiment surrounding HB 1249 is generally supportive among healthcare professionals and advocacy groups who see the establishment of a reporting system as vital for patient safety and public health. However, there may be concerns regarding the compliance burden on manufacturers and the implications of potential confidentiality issues for proprietary information. Overall, the bill is viewed positively for its intentions to prevent drug shortages and ensure essential medicines are accessible when needed.
Contention
Notable points of contention include the balance between maintaining confidentiality for manufacturers regarding business practices and the need for public access to information regarding drug availability. Additionally, the responsibilities imposed on manufacturers to report shortages within specific timeframes may be seen as an added regulatory burden. The challenge will lie in ensuring that the reporting system is effective without overstepping boundaries that could hinder pharmaceutical innovation or lead to unintended consequences for drug distribution.
Establishing the Compliance Review and Reporting Program; imposing duties on the Department of Health and the Department of Human Services; and imposing penalties.
Establishing the Office of New Pennsylvanians and providing for its powers and duties; establishing the Office of New Pennsylvanians Restricted Account; and establishing the Advisory Committee to Office of New Pennsylvanians and providing for its powers, duties and membership.
Establishing the Veterans' Housing Assistance Program; and imposing duties on Pennsylvania Housing Finance Agency and Department of Military and Veterans Affairs.
Providing for opioid stewardship; establishing the Opioid Reparation and Accountability Fund and the Opiate Epidemic Response Advisory Council; and imposing duties on the Department of Health, the Department of Human Services and the Department of Drug and Alcohol Programs.